NextCure (NXTC) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
24 Apr, 2026Voting matters and shareholder proposals
Election of two Class I Directors: Anne Borgman, M.D. and John G. Houston, Ph.D. are nominated for election.
Ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Advisory approval of executive compensation for named executive officers.
Approval of an amendment and restatement of the 2019 Omnibus Incentive Plan, including an increase in authorized shares for issuance.
Proxies are authorized to vote on other business that may properly come before the meeting.
Board of directors and corporate governance
Two nominees are presented for election to the board as Class I Directors.
Executive compensation and say-on-pay
Advisory vote is sought for the compensation paid to named executive officers.
Amendment to the 2019 Omnibus Incentive Plan includes increasing the number of shares available for executive and employee incentives.
Latest events from NextCure
- All-stock merger with Avere and $320M financing announced as net loss narrows to $14.9M.NXTC
Q2 2026 - Once-weekly oral IL-23RA shows strong efficacy and safety, targeting multibillion-dollar markets.NXTC
Corporate presentation - All proposals were approved, with no stockholder questions or comments submitted.NXTC
AGM 2026 - SIM0505 achieved 55% ORR and favorable safety in gynecologic cancers, supporting further trials.NXTC
KOL event - Two novel ADCs in Phase 1 trials show early promise for solid tumors, with 2026 milestones ahead.NXTC
Corporate presentation - Net loss narrowed to $9.8M in Q1 2026, but ongoing funding is needed for advancing ADC trials.NXTC
Q1 2026 - Shareholders will vote on director elections, auditor ratification, executive pay, and incentive plan expansion.NXTC
Proxy filing - Stable net loss and robust R&D investment position for major clinical milestones in 2026.NXTC
Q4 2025 - NC-181 shows promise as a safer, targeted Alzheimer's therapy with IND filing set for 2025.NXTC
H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference